## Leah A Comment

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4387640/publications.pdf

Version: 2024-02-01

1937685 1720034 8 182 4 7 citations h-index g-index papers 8 8 8 248 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Bayesian data fusion: Probabilistic sensitivity analysis for unmeasured confounding using informative priors based on secondary data. Biometrics, 2022, 78, 730-741.	1.4	2
2	The use of external control data for predictions and futility interim analyses in clinical trials. Neuro-Oncology, 2022, 24, 247-256.	1.2	29
3	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 732-739.	3.7	5
4	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discovery, 2021, 11, 282-292.	9.4	132
5	Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP) Journal of Clinical Oncology, 2021, 39, 142-142.	1.6	О
6	Association and interplay of surgeon and hospital volume with mortality after open abdominal aortic aneurysm repair in the modern era. Journal of Vascular Surgery, 2021, 73, 1593-1602.e7.	1.1	6
7	Abstract 864: Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC). Cancer Research, 2021, 81, 864-864.	0.9	4
8	Evidenceâ€Based Development and Clinical Use of Precision Oncology Therapeutics. Clinical Pharmacology and Therapeutics, 2020, 108, 440-443.	4.7	4